This position involves statistical analyses and programming of large scale international clinical trials. Qualified candidates will have advanced formal training in statistics or biostatistics including design and analysis of observational and experimental studies, and strong statistical computing skills The incumbent will work in collaboration with the Director of Biostatistics and Sr. Investigators within the TIMI Study Group to develop statistical analyses for investigational protocols. There will be the opportunity for career development with respect to authorship opportunities for journal manuscripts and abstracts/posters for professional scientific meetings.
Collaborate with Sr. Investigators to develop and perform statistical analyses (including planning, programming, analysis, interpretation and writing of results) for investigational protocols, subgroup and post-hoc projects and registry databases ending with preparation of manuscripts, abstracts and presentations at scientific meetings.
Determine and/or verify correct statistical testing to be performed in each analysis request.
Possess a solid understanding of the purpose, objectives and goals of each trial.
Rearranges data in a format that allows for accurate use as well as possible integration and pooling across trials.
Assure the maintenance of an up-to-date electronic archive recording data requests, statistical analyses, results, and data transmissions performed.
Maintain department service standards as outlined in the BWH Code of Conduct
Performs other duties as required and as appropriate.
Masters degree in biostatistics, statistics, or related field
3 years of related experience
high proficiency in statistical computing; SAS experience strongly preferred
Additional Salary Information: Salary to be determined and commensurate with experience
About Brigham and Women's Hospital, TIMI Study Group
The TIMI Study Group is an academic research organization at Brigham and Women's Hospital, Department of Cardiovascular Medicine.
Since its inception in 1984, the principal goal of the TIMI Study Group has been to conduct high quality
clinical trials that enhance the care of patients suffering from cardiovascular disease and its risk factors.
TIMI has led a wide array of phase 1 to phase 4 trials, as well as registries. These have ranged in size
from less than 30 to more than 25,000 subjects. The interventions studied include fibrinolytic,
antithrombotic, anti-platelet, anti-ischemic, lipid lowering, anti-inflammatory, and anti-diabetic agents as
well as percutaneous coronary intervention. In addition, the TIMI Study Group has used its growing
database of more than 300,000 subjects and their clinical findings, electrocardiograms, angiograms,
biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk
factors. An important corollary goal has been to train the next generation of clinical investigators. TIMI is
especially proud of these trainees who have assumed leadership positions in leading institutions
around the world.